ERNAW — Ernexa Therapeutics Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 748592 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
No quarterly fundamentals indexed for this ticker.

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $949.47B $1064.74
JNJ JOHNSON & JOHNSON $554.09B $230.18
ABBV AbbVie Inc. $376.54B $213.12
MRK Merck & Co., Inc. $295.69B $119.72
AZN ASTRAZENECA PLC $290.30B $187.19

News headlines (Yahoo Finance, 1h cache)

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
2026-05-20 14:45 · Yahoo
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
2026-05-20 12:31 · Yahoo
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
2026-05-18 14:35 · Yahoo
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
2026-05-11 13:15 · Yahoo
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models
2026-05-06 14:40 · Yahoo
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
2026-05-06 12:33 · Yahoo
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
2026-04-30 13:00 · Yahoo
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
2026-03-31 12:55 · Yahoo
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
2026-02-20 14:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.